Instructions for Use
800.456.2255

AVONEX access and reimbursement

Broad formulary access to the #1 prescribed interferon for relapsing MS1,2,a,b

Preferred on [Express Scripts] and [Anthem]1,c

No generic substitution3 for AVONEX

~8 out of 10 commercially insured patients pay $30 or less per month for AVONEX1,d

Biogen Copay Program

The Biogen Copay Program may lower medication cost to as little as $0 for eligible patients with commercial insurance.e

When cost may be a concern for your patients, Biogen may be able to help them start and continue on a Biogen therapy. We will work with your patients based on their individual needs.

Biogen Support Services offers a variety of different financial and insurance resources, including:

  • Communicating with insurance companies to clarify and confirm coverage, including assistance with the Prior Authorization process and denied claims
  • Insurance counseling that educates uninsured and underinsured patients on government insurance programs
  • If your patients need assistance with the Affordable Care Act, we can help patients and providers become familiar with insurance options
  • Financial assistance options, including the Biogen Copay Program or other possible financial assistance, when applicable

Please contact your Biogen Access & Reimbursement Manager (ARM) for more information on these resources or call Biogen Support Services at 1-800-456-2255 if you have any questions or concerns about patient access to AVONEX.

a74% of patients in the US have unrestricted access to AVONEX, defined as requiring a simple prior authorization that does not include an embedded step. Source: MMIT database as of April 8, 2021.1
bThis information is an estimate derived from the following IQVIA information service: IQVIA NPA® NBRx monthly data for the period March 2015-February 2021.
 cSource: MMIT database as of April 15, 2021.1
 dBased on Symphony claims data, January 2020–December 2020: 77% paid <$20, 84% paid <$40.1
eThere is an annual cap on the amount of assistance that patients can receive over a one-year period. Federal and state laws and other factors may prevent or otherwise restrict eligibility. People covered by Medicare, Medicaid, the VA/DoD, or any other federal plans are not eligible to enroll. Patients are eligible to enroll in the Biogen Copay Program for as long as it is offered and they are treated with a Biogen relapsing MS medication.
Getting started

Get your patients started on therapy with the AVONEX Start Form

Download Start Form

Support for your patients
is here
Biogen Case Managers and Nurse Educators are here to help your patients start and continue on AVONEX

Get support today
Streamline the process and support patient adherence

myBiogen is an online resource for starting and keeping patients on therapy

Sign up at myBiogen.com

Indication

AVONEX® (interferon beta-1a) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

CONTRAINDICATIONS

  • AVONEX is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, or any other component of the formulation
  • The formerly available lyophilized vial formulation of AVONEX is contraindicated in patients with a history of hypersensitivity to albumin (human)

WARNINGS AND PRECAUTIONS

Depression, Suicide, and Psychotic Disorders

  • Patients treated with AVONEX and their caregivers should be advised to report immediately any symptoms of depression, suicidal ideation, and/or psychosis to their prescribing physician. If a patient develops depression or other severe psychiatric symptoms, cessation of AVONEX therapy should be considered. Depression and suicide have been reported to occur with increased frequency in patients receiving AVONEX. Additionally, there have been postmarketing reports of depression, suicidal ideation, and/or development of new or worsening of other pre-existing psychiatric disorders, including psychosis. For some of these patients, symptoms of depression improved upon cessation of AVONEX

Hepatic Injury

  • Severe hepatic injury, including cases of hepatic failure, has been reported rarely in patients taking AVONEX. Asymptomatic elevation of hepatic transaminases has also been reported, and in some patients has recurred upon rechallenge with AVONEX. In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury. The potential risk of AVONEX used in combination with known hepatotoxic drugs or other products (e.g., alcohol) should be considered prior to starting AVONEX, or before starting hepatotoxic drugs. Patients should be monitored for signs of hepatic injury

Anaphylaxis and Other Allergic-Reactions

  • Anaphylaxis has been reported as a rare complication of AVONEX use. Other allergic reactions have included dyspnea, orolingual edema, skin rash and urticaria. Discontinue AVONEX if anaphylaxis or other allergic reactions occur

Injection Site Reactions Including Necrosis

  • Injection site reactions, including injection site necrosis, can occur with the use of interferon beta products, including AVONEX. In controlled clinical trials, injection site reactions (e.g., injection site pain, bruising or erythema) occurred in 18% of patients receiving AVONEX and 13% in the placebo group. These reactions included injection site inflammation (6%), injection site pain (8%), injection site mass (<1%), nonspecific reactions. Injection site abscesses and cellulitis and injection site necrosis have been reported in the postmarketing setting with interferon beta products, including AVONEX. Some cases required treatment with hospitalization for surgical drainage and intravenous antibiotics. Periodically evaluate patient understanding and use of aseptic self-injection techniques and procedures, particularly if injection site necrosis has occurred. Whether to discontinue therapy following a single site of necrosis is dependent on the extent of necrosis. For patients who continue therapy with AVONEX after injection site necrosis has occurred, avoid administration of AVONEX into the affected area until it is fully healed. If multiple lesions occur, change injection site or discontinue therapy until healing occurs

Congestive Heart Failure

  • Patients with pre-existing congestive heart failure should be monitored for worsening of their cardiac condition during initiation of and continued treatment with AVONEX. While beta interferons do not have any known direct cardiac toxicity, during the postmarketing period cases of congestive heart failure, cardiomyopathy, and cardiomyopathy with congestive heart failure have been reported in patients without known predisposition to these events, and without other etiologies being established

Decreased Peripheral Blood Counts

  • Decreased peripheral blood counts in all cell lines, including rare pancytopenia and thrombocytopenia, have been reported from postmarketing experience in AVONEX-treated patients

Thrombotic Microangiopathy

  • Cases of thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, some fatal, have been reported with interferon beta products, including AVONEX. Cases have been reported several weeks to years after starting interferon beta products. Discontinue AVONEX if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated

Seizures

  • Seizures have been temporally associated with the use of beta interferons in clinical trials and postmarketing safety surveillance. It is not known whether these events were related to the effects of multiple sclerosis alone, to AVONEX, or to a combination of both

Autoimmune Disorders

  • Postmarketing reports of autoimmune disorders of multiple target organs in AVONEX-treated patients included idiopathic thrombocytopenia, hyper- and hypothyroidism, and rare cases of autoimmune hepatitis. If AVONEX-treated patients develop a new autoimmune disorder, consider stopping the therapy

Laboratory Tests

  • In addition to those laboratory tests normally required for monitoring patients with multiple sclerosis, complete blood and differential white blood cell counts, platelet counts, and blood chemistries, including liver function tests, are recommended during AVONEX therapy. Patients with myelosuppression may require more intensive monitoring of complete blood cell counts, with differential and platelet counts. Thyroid function should be monitored periodically. If patients have or develop symptoms of thyroid dysfunction (hypo- or hyperthyroidism), thyroid function tests should be performed according to standard medical practice

MOST COMMON SIDE EFFECTS

  • The most commonly reported adverse reactions (at least 5% more frequent on AVONEX than on placebo) were flu-like symptoms. Symptoms can include chills, fever, myalgia and asthenia occurring within hours to days following an injection. The most frequently reported adverse reactions resulting in clinical intervention were flu-like symptoms and depression

References: 1. Biogen. Data on file. Cambridge, MA. 2. AVONEX Prescribing Information. Cambridge, MA: Biogen. 3. AVONEX. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/Treating-MS/Medications/Avonex. Accessed April 6, 2021. 

Start AVONEX
Getting started Dosing Support program
Efficacy
AVONEX efficacy Pivotal trials Long-term follow-up studies
Safety
Well-understood safety profile Adverse reactions Managing common side effects Special populations
Access and reimbursement
Access and
reimbursement

©2021 Biogen. All rights reserved. 12/21 AVX-US-0587 v3
All trademarks are the property of their respective owners.
For US healthcare professionals only.